Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits ...

Generic drugmaker Sandoz (OTCQX:SDZXF) announced on Monday the filing of an antitrust lawsuit alleging that Amgen ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra (tarlatamab-dlle) has met its primary endpoint at a planned interim ...

Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s ...

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...

UBS raised the firm’s price target on Amgen (AMGN) to $319 from $315 and keeps a Neutral rating on the shares. The firm is expecting an in-line ...

The health sector faces numerous challenges, including counterfeit Ozempic, a Sandoz antitrust lawsuit against Amgen, Trump's ...